Silihan lan utang jangka dawa perusahaan: Inspira Technologies Oxy (IINN)

A research center in Israel is developing innovative non-invasive blood oxygenation methods as an alternative to ventilators, and Inspira Technologies Oxy (IINN) is expanding its global distributor network while seeking FDA certifications without pursuing mergers. Inspira Technologies Oxy (IINN) has outsourced production to external plants to minimize risks, and its long-term debt stands at 0.00. The historical price action shown below clearly illustrates the issuer's financial condition.

The scaling of Inspira Technologies Oxy therapeutic systems through global alliances is reflected in the company's long-term debt dynamics on the GURU.Markets platform. This indicator aggregates multi-year credit obligations and bond loans, allowing investors to assess the issuer's financial resilience to recession and bankruptcy risk by analyzing the volume of borrowed capital required to maintain business liquidity.